Molecular targeting and pharmacogenomics in the management of advanced bladder cancer

Cancer

Volumn 97, Issue 8 SUPPL., 2003, Pages 2083-2089

  Raghavan, Derek ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; PROTEIN DERIVATIVE; PROTEIN P16; PROTEIN P21; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME 9; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TARGETING; GENE MUTATION; GENETIC ASSOCIATION; HEREDITY; HETEROZYGOSITY; HUMAN; METASTASIS; ONCOGENE; ONCOGENE MYC; ONCOGENE RAS; P53 SUPPRESSOR GENE; PATHOGENESIS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RACE; SUPPRESSOR GENE;

EID: 0037445965     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11281     Document Type: Conference Paper

References (42)

1. Koss LG. Tumors of the urinary bladder. Atlas of Tumor Pathology, second Series, fascicle 11. Washington DC: Armed Forces Institute of Pathology, 1975.
2. Johansson SL, Anderstrom CR. Primary adenocarcinoma of the urinary bladder and urachus. In: Raghavan D, Brecher MI, Johnson DR, Meropol NJ, Moots PJ, Thigpen JT, editors. Textbook of uncommon cancer. New York: Wiley-Liss, 1999: 29-43.
3. Sternberg CN, Swanson DA. Non-transitional cell bladder cancer. In: Raghavan D, Scher HI, Leibel S, Lange PH, editors. Principles and practice of genitourinary oncology. Philadelphia: Lippincott-Raven, 1997:315-330.
4. Brown JL, Russell PJ, Philips J, Wotherspoon J, Raghavan D. Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity. Br J Cancer. 1990;61:369-376.
5. Loehrer PI, Einhorn LH, Elson PI, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066-1072.
6. Raghavan D, Shipley WU, Gamick MB, et al. Biology and management of bladder cancer. N Engl J Med. 1990;322: 1129-1133.
7. Raghavan D. Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer. In press.
8. Russell PI, Brown JL, Grimmond SM, Raghavan D. Molecular biology of urological tumors. Br J Urol. 1990;65:121-130.
9. Limas C, Lange PH, Fraley EE, Vessella RL. ABH antigens in transitional cell tumors of the urinary bladder: correlation with the clinical course. Cancer. 1979;44:2099-2107.
10. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994;54:784-788.
11. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. New Engl J Med. 1994;331:1259-1264.
12. Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A. 1990;97:9047-9051.
13. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998; 58:1090-1094.
14. WAF1/C1PI expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90:1072-1079.
15. Tamirni Y, Bringuier PP, Smit F, et al. Homozygous deletions ofpI6(INK4) occur frequently in bilharziasis-associated bladder cancer. Int J Cancer. 1996;65:840-845.
16. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985;1:366-368.
17. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer. 1994;69:1120-1125.
18. Seymour GJ, Walsh MD, Levin MR, Strutton G, Gardiner RA. Transferrin receptor expression by human bladder transitional cell caricnoma. Urol Res. 1987;15:341-344.
19. Bochner B, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87:1603-1612.
20. Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst. 1997;89:219-227.
21. Logothetis CJ, Dexeus FR, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050-1055.
22. Meyers FJ, Palmer JM, Freiha FS, et al. The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study. J Urol. 1985;134:1118-1121.
23. Scher H, Herr H, Sternberg C, et al. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. Br J Urol. 1989;64:250.
24. Pendyala L, Velagapudi S, Toth K, Glaves D, Creaven PJ, Raghavan D. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res. 1997;3:793-798.
25. Cote RJ, Esrig D, Groshen S, et al. p53 and treatment of bladder cancer. Nature. 1997;385:123-124.
26. Sarkis A, Bajorin D, Reuter V, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995; 13:1384-1390.
27. Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145: 459-467.
28. Siu LL, Banerjee D, Khurana RJ, et al. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle invasive urothelial transitional cell carcinoma. Clin Cancer Res. 1998;4:559-565.
29. Kelley SL, Basu A, Teicher BA, et al. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988;241:1813-1815.
30. Satoh M, Kloth DM, Kadhim SA, et al. Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis. Cancer Res. 1993;53:1829-1832.
31. Kielb SJ, Shah NL, Rubin MA, Sanda MG. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. J Urol. 2001;166:482-487.
32. Christen RD, Horn DK, Porter DC, et al. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest. 1990;86:1632-1640.
33. Fan Z, Baselga J, Masui H, et al. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloro-platinum on well established A-431 cell xenografts. Cancer Res. 1993;53:4637-4642.
34. Petrylak DP, Scher HI, Reuter V, O'Brien JP, Cordon-Cardo C. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol. 1994; 3:835-840.
35. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer. 1998;34:1493-1499.
36. Harris BE, Song R, Soong S, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990;50:197-201.
37. Fleming RA, Milano GA, Gaspard MR, et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer. 1993;29A:740-744.
38. Mizutani Y, Wada H, Fukushima M, et al. The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur J Cancer. 2001;37:569-575.
39. Harris JW, Rahman A, Kim BR, et al. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 1994;54:4026-4035.
40. Royer I, Monsarrat B, Sonnier M, et al. Metabolism of docetaxel by human cytochrome P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 1996;56: 58-65.
41. Waxman DJ. Glutathione s-transferases: Role in alkylating agent resistance and possible target for modulation chemotherapy - a review. Cancer Res. 1990;50:6449-6454.
42. Gupta E, Lestingi TM, Mick R, et al. Metabolic rate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723-3725.